DOXIL (LIPOSOMAL) Drug Patent Profile

When do Doxil (liposomal) patents expire, and when can generic versions of Doxil (liposomal) launch?

Doxil (liposomal) is a drug marketed by Baxter Hlthcare Corp and is included in one NDA.

The generic ingredient in DOXIL (LIPOSOMAL) is doxorubicin hydrochloride. There are seventeen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the doxorubicin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Doxil (liposomal)

A generic version of DOXIL (LIPOSOMAL) was approved as doxorubicin hydrochloride by PFIZER on December 23^rd, 1987.

Summary for DOXIL (LIPOSOMAL)

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for DOXIL (LIPOSOMAL)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare Corp	DOXIL (LIPOSOMAL)	doxorubicin hydrochloride	INJECTABLE, LIPOSOMAL;INJECTION	050718-001	Nov 17, 1995	AB	RX	Yes	No
Baxter Hlthcare Corp	DOXIL (LIPOSOMAL)	doxorubicin hydrochloride	INJECTABLE, LIPOSOMAL;INJECTION	050718-002	Jun 13, 2000	AB	RX	Yes	No

International Patents for DOXIL (LIPOSOMAL)

See the table below for patents covering DOXIL (LIPOSOMAL) around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	0134982
Germany	19675048
Japan	H05505173

Supplementary Protection Certificates for DOXIL (LIPOSOMAL)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0496835	C960031	Netherlands		PRODUCT NAME: DOXORUBICINESULFAAT VERKREGEN UIT DOXORUBICINEHYDROCHLORIDE EN AMMONIUMSULFAAT; REGISTRATION NO/DATE: EU/1/96/011/001 - EU/1/96/011/002 19960621
0496835	SPC/GB96/053	United Kingdom		PRODUCT NAME: DOXORUBICIN SULPHATE; REGISTERED: UK EU/1/96/011/001 19960621; UK EU/1/96/011/002 19960621
0496835	96C0047	Belgium		PRODUCT NAME: ACIDE IBANDRONIQUE; REGISTRATION NO/DATE: EU/1/96/012/001 19960625

Investment Scenario and Fundamentals Analysis for DOXIL (Liposomal Doxorubicin)

Last updated: February 20, 2026

What is the current market position of DOXIL?

DOXIL (liposomal doxorubicin HCl) is a chemotherapeutic agent approved primarily for ovarian cancer, multiple myeloma, AIDS-related Kaposi's sarcoma, and other indications. Its unique liposomal formulation extends half-life, reduces cardiotoxicity compared to conventional doxorubicin, and improves tumor targeting.

As of 2023, DOXIL remains a leading agent within the niche of liposomal chemotherapy drugs. Its annual sales are approximately $200 million globally, with the majority generated in the United States. Market penetration is higher in specialty oncology clinics, especially for indications with unmet medical needs.

What are the key drivers influencing DOXIL's investment potential?

Regulatory and patent landscape

• Launched in 1995 by Johnson & Johnson (J&J) via its subsidiary, Janssen Pharmaceuticals.
• Patent protection expired around 2011, leading to generic versions entering the market.
• The original patent expiration prompted J&J to focus on lifecycle management through additional indications and new formulations.

Market dynamics

• The advent of biosimilars and generics has resulted in significant price erosion.
• The U.S. FDA approved the first biosimilar of doxorubicin in 2015. Several liposomal doxorubicin generics are now available.
• Despite generic competition, DOXIL maintains a niche for specific indications owing to its formulation advantages.

Competitive landscape

Competitor	Product Name	Formulation	Market Share (2023)	Indications
Generic manufacturers	Multiple biosimilars	Conventional doxorubicin	>80%	Broad chemotherapy use
Janssen (J&J)	DOXIL (brand)	Liposomal doxorubicin	20%	Ovarian, multiple myeloma, Kaposi's sarcoma

R&D pipeline and lifecycle management

• Janssen has explored new formulations, including liposomal variants with targeted delivery.
• Ongoing research involves combining DOXIL with immune checkpoint inhibitors for synergistic effects.
• Limited pipeline expansion exists as competition shifts focus towards targeted therapies and immunotherapies.

Clinical efficacy and safety profile

• Overall survival benefits confirmed in multiple phase III trials.
• Lower cardiotoxicity compared to conventional doxorubicin.
• Side effect profile includes palmar-plantar erythrodysesthesia, mucositis, neutropenia.

Pricing and reimbursement

• The average wholesale price (AWP) for DOXIL is around $5,000 per 50 mg vial.
• Insurance coverage remains robust for approved indications; however, reimbursement depends on regional policies.
• Price erosion from generics impacts profitability; however, premium pricing persists for branded formulations in specific markets.

What are the financial and strategic considerations?

Revenue sustainability

• Given patent expiration and generic competition, revenue has declined from peak levels.
• Niche positioning and formulation advantages sustain some higher-margin sales.
• New combinations and expanded indications could stabilize or increase revenue streams.

Market entry barriers

• Established presence of biosimilars increases competition.
• Janssen’s existing market channels and brand recognition remain assets.
• Regulatory hurdles for new liposomal formulations can delay market entry for competitors.

Investment risks

• Patent expiry effects and increasing generic competition threaten margins.
• Potential for regulatory changes impacting reimbursement.
• R&D pipeline uncertainties, especially with shifting therapeutic paradigms towards immuno-oncology.

Opportunities for growth

• Expanding label for combination therapies involving immune checkpoint inhibitors.
• Developing next-generation liposomal formulations with targeted delivery.
• Entering emerging markets with increasing cancer prevalence.

What is the outlook for future investment?

• Pharmaceutical companies with established liposomal platforms and strong oncology pipelines remain best positioned.
• The market for liposomal chemotherapies will decline gradually due to increasing biosimilar competition.
• Strategic investments should prioritize combination therapies and improved formulations.

Key Takeaways

• DOXIL's revenue is plateaued and declining due to patent expiry and generic competition.
• Its niche positioning in specific indications supports continued, though limited, revenue streams.
• Innovation efforts focus on combination therapies and advanced liposomal formulations.
• Market entry barriers for competitors are moderate, hindered by regulatory and clinical development costs.
• Long-term growth prospects hinge on lifecycle management strategies and expanding indications.

FAQs

1. How long does patent exclusivity last for DOXIL?

The original patent expired around 2011, leading to generic competition. Since then, exclusivity relies on formulation patents and secondary patents.

2. Are biosimilars approved for liposomal doxorubicin?

Biosimilars for conventional doxorubicin exist since 2015, but liposomal formulations have limited biosimilar options due to complex manufacturing processes and regulatory hurdles.

3. What are the primary indications for DOXIL?

Ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma are the main approved uses. Expansion into other cancers is experimental.

4. How does DOXIL compare in cost to generic doxorubicin?

Branded DOXIL costs approximately $5,000 per 50 mg vial, whereas generic doxorubicin is priced around $50, representing a 100-fold difference.

5. What are the primary risks for investment in DOXIL?

Patent expiration effects, generic competition, regulatory reimbursement changes, and limited pipeline innovation.

References

1. Johnson & Johnson. (2022). Annual Report.
2. U.S. Food and Drug Administration. (2015). Approval of biosimilar doxorubicin.
3. MarketsandMarkets. (2023). Liposomal Drug Delivery Market Analysis.
4. EvaluatePharma. (2023). Oncology Drug Market Data.
5. Food and Drug Administration. (2022). Drug Patent Expiry Data.